Royalty Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,378	2,264	2,355	2,237	2,289
Revenue Growth (YoY)	5.06%	-3.86%	5.24%	-2.28%	7.87%
Cost of Revenue	-295.84	732.46	560.66	904.24	452.84
Gross Profit	2,674	1,531	1,794	1,333	1,837
Selling, General & Admin	573.48	236.67	249.75	227.3	182.83
Research & Development	452	2	52	177.11	200.08
Amortization of Goodwill & Intangibles	-	-	-	5.67	23
Operating Expenses	1,115	238.67	301.75	410.08	405.91
Operating Income	1,560	1,292	1,492	922.89	1,431
Interest Expense	-307.66	-225.51	-187.19	-187.96	-166.14
Interest & Investment Income	33.59	47.34	72.29	78.34	53.54
Earnings From Equity Investments	29.09	29.61	28.88	-8.97	-19.49
Other Non Operating Income (Expenses)	-14.35	-7.53	-24.03	81.86	-27.21
EBT Excluding Unusual Items	1,300	1,136	1,382	886.15	1,271
Gain (Loss) on Sale of Investments	24.01	194.46	317.98	-40.26	-30.21
Asset Writedown	-	-	-	-615.83	-
Pretax Income	1,324	1,331	1,700	230.06	1,241
Earnings From Continuing Operations	1,324	1,331	1,700	230.06	1,241
Minority Interest in Earnings	-553.25	-471.83	-565.25	-187.23	-621.47
Net Income	770.95	858.98	1,135	42.83	619.73
Net Income to Common	770.95	858.98	1,135	42.83	619.73
Net Income Growth	-10.25%	-24.31%	2549.50%	-93.09%	-36.44%
Shares Outstanding (Basic)	430	448	448	438	415
Shares Outstanding (Diluted)	564	594	603	438	415
Shares Change (YoY)	-4.99%	-1.46%	37.66%	5.59%	10.48%
EPS (Basic)	1.79	1.92	2.54	0.10	1.49
EPS (Diluted)	1.78	1.91	2.53	0.10	1.49
EPS Growth	-6.83%	-24.54%	2490.74%	-93.44%	12.97%
Dividend Per Share	0.880	0.840	0.800	0.760	0.680
Dividend Growth	4.76%	5.00%	5.26%	11.77%	126.67%
Gross Margin	112.44%	67.64%	76.19%	59.58%	80.22%
Operating Margin	65.58%	57.10%	63.37%	41.25%	62.49%
Profit Margin	32.42%	37.95%	48.20%	1.92%	27.07%
EBITDA	1,563	-	1,498	928.56	1,454
EBITDA Margin	65.74%	-	63.61%	41.50%	63.50%
D&A For EBITDA	3.85	-	5.67	5.67	23
EBIT	1,560	1,292	1,492	922.89	1,431
EBIT Margin	65.58%	57.10%	63.37%	41.25%	62.49%
Revenue as Reported	2,378	2,264	2,355	2,237	2,289

Updated Feb 11, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q